New Alzheimer Drugs on the Horizon!

More documents

Recommendations

Info

Aducanumab is a pioneer in the fight against AD. To date, there have been no other medications that destroy brain plaques. Current drugs decelerate the disease process temporarily but are unable to halt completely its progression. Aducanumab significantly retards plaque formation. The drug is the brainchild of the Biogen company, based in Massachusetts. Clinical testing is in the final Phase 3 stage. This segment of evaluation involves a large study group of 1,350 patients over five years. Thorough testing on a broad scale is required before the drug can be marketed. Analysts expect that within three years, the data will indicate whether Adu can mab is the "Goldilocks" drug, the "just right" formulation that will resolve AD. Researchers are optimistic regarding the drug's potential.
JOINING CRUSADETHE Also in the testing phase are three other medications, solanezumab, gantenerumab, and crenezumab. Solanezumab - The drug manufacturer Eli Lilly is testing this drug. Solanezumab is also designed to attack brain plaques. The drug appears to help mild AD. Gantenerumab - Roche Pharmaceuticals has produced this anti-amyloid drug. Data from spinal fluid tests and brain scans are promising. Crenezumab - The Genentech company has formulated this drug, targeted to mild AD. Research is now in the Phase 3 stage.
Page 1 and 2: New Alzhei
Page 3 and 4: Plaques And Tangles The development
Page 5 and 6: LANDMARK S T U D Y The Adu can mab
Page 7: SIDE EFFECT Most of the study parti
Page 11 and 12: CHOLINESTERASE INHIBITORS (CIs) Pla
Page 13 and 14: Memantine Under the brand name Name
Page 15 and 16: Solanezumab - Research on solanezum
Page 17 and 18: SOURCES 1. https://www.alzinfo.org/

New Alzheimer Drugs on the Horizon!

Create successful ePaper yourself

Delete template?

Save as template?